Imaavy
What Imaavy is used for
Imaavy is indicated as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult and adolescent patients aged 12 years of age and older who are anti‑acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Imaavy
- Active substance
- nipocalimab
- Disease area
- Myasthenia Gravis
- Medicine group
- Immunosuppressants
- ATC code
- L04AL03
- Marketing authorisation holder
- Janssen Cilag International NV
- Authorised in the EU since
- 2025
Official information
In the USA
Same active substance: Imaavy
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Imaavy used for?
Imaavy is indicated as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult and adolescent patients aged 12 years of age and older who are anti‑acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.
What is the active substance in Imaavy?
Imaavy contains nipocalimab.
Who makes Imaavy?
The EU marketing authorisation holder is Janssen Cilag International NV.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU